BibSonomy :: user :: kanefendt

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome

E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom. Ann.Oncol. 18(10):1745-1747 (2007)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

T. F. Chu, M. A. Rupnick, R. Kerkela, S. M. Dallabrida, D. Zurakowski, L. Nguyen, K. Woulfe, E. Pravda, F. Cassiola, J. Desai, S. George, J. A. Morgan, D. M. Harris, N. S. Ismail, J. H. Chen, F. J. Schoen, A. D. van den Abbeele, G. D. Demetri, T. Force, and M. H. Chen. Lancet 370(9604):2011-2019 (2007)

3 years and 5 months ago

by kanefendt

1

& Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use

(0)

URLDOITeX

The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor

A. P. Dei Tos. Int.J.Biol.Markers 22(1 Suppl 4):S3-S9 (2007)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges

F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro. Int.J.Biol.Markers 22(1 Suppl 4):S10-S23 (2007)

3 years and 5 months ago

by kanefendt

2

& Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use

(0)

URLDOITeX

Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib

E. Chorianopoulos, D. Jager, H. A. Katus, and N. Frey. Clin.Res.Cardiol. 96(11):829-830 (2007)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Angiogenesis: an organizing principle for drug discovery?

J. Folkman. Nat.Rev.Drug Discov. 6(4):273-286 (2007)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

T. Force, D. S. Krause, and R. A. van Etten. Nat.Rev.Cancer 7(5):332-344 (2007)

3 years and 5 months ago

by kanefendt

1

& Adaptor Antibodies Benzenesulfonates Biological Delivery Diseases Drug Enzyme Heart Human Humans Indoles Inhibitors Kinase Kinases Models Monoclonal Mutation Neoplasms Protein Protein-Tyrosine Proteins Proto-Oncogene Pyridines Pyrroles Quinazolines Research Signal Systems Transducing Tyrosine adverse antagonists c-abl cells chemically development drug effects growth induced inhibitors physiology protein response therapy toxicity

(0)

URLDOITeX

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel. Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)

3 years and 5 months ago

by kanefendt

1

& A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity

(0)

URLDOITeX

Molecular basis for sunitinib efficacy and future clinical development

S. Faivre, G. Demetri, W. Sargent, and E. Raymond. Nat.Rev.Drug Discov. 6(9):734-745 (2007)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

The clinical toxicity profile of vascular endothelial growth factor VEGF and vascular endothelial growth factor receptor VEGFR targeting angiogenesis inhibitors; a review

F. A. Eskens, and J. Verweij. Eur.J.Cancer 42(18):3127-3139 (2006)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment

A. Gampel, L. Moss, M. C. Jones, V. Brunton, J. C. Norman, and H. Mellor. Blood 108(8):2624-2631 (2006)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients

S. Nadar, A. D. Blann, and G. Y. Lip. Am.J.Hypertens. 19(9):970-977 (2006)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

H. M. Verheul, and H. M. Pinedo. Nat.Rev.Cancer 7(6):475-485 (2007)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis

A. Y. Debrah, S. Mand, S. Specht, Y. Marfo-Debrekyei, L. Batsa, K. Pfarr, J. Larbi, B. Lawson, M. Taylor, O. Adjei, and A. Hoerauf. PLoS.Pathog. 2(9):e92 (2006)

3 years and 5 months ago

by kanefendt

1

& Adult Aged Animals C Data Doxycycline Elephantiasis Endothelial Factor Female Filarial Filaricides Growth Humans Hydrocele Intercellular Lymphatic Lymphedema Male Microfilaria Middle Molecular Outcome Parasitemia Peptides Plasma Proteins Receptor-3 Research Sequence Signaling System Testicular Testis Treatment Vascular Vessels Wolbachia and antagonists blood drug effects immunology inhibitors isolation parasitology pathology physiology protein purification therapeutic therapy ultrasonography use

(0)

URLDOITeX

Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

M. J. Cuadrado, P. Buendia, F. Velasco, M. A. Aguirre, N. Barbarroja, L. A. Torres, M. Khamashta, and C. Lopez-Pedrera. J.Thromb.Haemost. 4(11):2461-2469 (2006)

3 years and 5 months ago

by kanefendt

1

& A Adolescent Adult Aged Antibodies Antiphospholipid Cells Cultured Endothelial Enzyme Expression Factor Female Gene Growth Human Humans Imidazoles Inhibitors Kinase Kinases MAP Male Middle Mitogen-Activated Monocytes Phenotype Protein Pyridines Receptor-1 Regulation Research Signaling Syndrome System Thromboplastin Thrombosis Tyrosine Vascular antagonists biosynthesis cells drug effects inhibitors metabolism p38 pathology pharmacology protein

(0)

URLDOITeX

Home blood-pressure monitoring in patients receiving sunitinib

M. Azizi, A. Chedid, and S. Oudard. N.Engl.J.Med. 358(1):95-97 (2008)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

Biomarker method validation in anticancer drug development

J. Cummings, T. H. Ward, A. Greystoke, M. Ranson, and C. Dive. Br.J.Pharmacol. 153(4):646-656 (2008)

3 years and 5 months ago

by kanefendt

1

& Adherence Agents Animals Antineoplastic Assay Biomarkers Cell Clinical Control Death Drug Enzyme-Linked Europe Evaluation Guideline Guidelines Humans Immunosorbent Keratin-18 Laboratories Mass Pharmacological Preclinical Proteins Quality Reproducibility Research Results Spectrometry Terminology Topic Trials analysis as drug effects jurisprudence legislation methods of pharmacology protein standards therapeutic use

(0)

URLDOITeX

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller. J Clin Oncol 26(11):1810-1816 (2008)

3 years and 5 months ago

by kanefendt

1

& Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use

(0)

URLDOITeX

How well do angiogenesis inhibitors work? Biomarkers of response prove elusive

V. Brower. J.Natl.Cancer Inst. 101(12):846-847 (2009)

3 years and 5 months ago

by kanefendt

1

(0)

URLDOITeX

bookmarks

publications (42)